Dubois' Lupus Erythematosus and Related Syndromes
- 10 Edición - 4 de diciembre de 2023
- Última edición
- Editores: Daniel J. Wallace, Bevra Hahn
- Idioma: Inglés
**Selected for 2025 Doody’s Core Titles® in Rheumatology**For more than 50 years, Dubois’ Lupus Erythematosus and Related Syndromes has been recognized internationally as… Leer más
Descripción
Descripción
**Selected for 2025 Doody’s Core Titles® in Rheumatology**
For more than 50 years, Dubois’ Lupus Erythematosus and Related Syndromes has been recognized internationally as the go-to clinical reference on lupus and other connective tissue diseases. From basic scientific principles to practical points of clinical management, the 10th edition provides extensive, authoritative coverage of systemic lupus erythematosus (SLE) and its related diseases in a logical, clearly written, user-friendly manner. It’s an ideal resource for rheumatologists and internal medicine practitioners who need a comprehensive clinical reference on all aspects of SLE, connective tissue diseases, and the antiphospholipid syndromes.
For more than 50 years, Dubois’ Lupus Erythematosus and Related Syndromes has been recognized internationally as the go-to clinical reference on lupus and other connective tissue diseases. From basic scientific principles to practical points of clinical management, the 10th edition provides extensive, authoritative coverage of systemic lupus erythematosus (SLE) and its related diseases in a logical, clearly written, user-friendly manner. It’s an ideal resource for rheumatologists and internal medicine practitioners who need a comprehensive clinical reference on all aspects of SLE, connective tissue diseases, and the antiphospholipid syndromes.
Puntos claves
Puntos claves
- Provides complete clinical coverage of every aspect of cutaneous and systemic lupus erythematosus, including definitions, pathogenesis, autoantibodies, clinical and laboratory features, management, prognosis, and patient education.
- Includes significant new content throughout: a new chapter on the endocrine system and hormones; newly distinct chapters on the heart and lung; new content on social disparities in lupus, clinical presentation of nephritis, and pulmonary hypertension; a new concluding chapter on future directions in the field; new basic science coverage of the microbiome, autoinflammatory, and monogenic lupus; and new coverage of diversity, inclusion, gender, compliance, and adherence.
- Offers a fresh perspective from two new associate editors and many new authors with representation from 30 countries.
- Contains an up-to-date overview of significant advances in cellular, molecular, and genetic technologies, including genetic advancements in identifying at-risk patients.
- Discusses the clinical management of related disorders such as Sjogren’s syndrome, scleroderma, polymyositis, and antiphospholipid syndrome (APS).
- Presents the knowledge and expertise of international contributors to provide new global perspectives on manifestations, diagnosis, and treatment.
- Features a vibrant, full-color format, with graphs, algorithms, differential diagnosis comparisons, new and improved figures, and schematic diagrams throughout.
De interès para
De interès para
Rheumatologists in training and in practice
Índice
Índice
SECTION 1 What Is Lupus?
1 History of Lupus
2 Definition and Classification of Lupus and Lupus-Related Disorders
3 The Epidemiology of Lupus
SECTION 2 Pathogenesis
4 Overview of Lupus Pathogenesis
5 Genetics of SLE
6 Single Gene Defects and Autoinflammation: Relation to Lupus
7 Epigenetics of Lupus
8 The Role of the Environment and Microbiome in Lupus
9 The Innate Immune System in SLE
10 B Cells and Generation of Antibodies
11 T cells
12 Immunoregulatory Cells and Networks in Lupus
13 Cytokines in Lupus
14 Metabolic Control of Immunopathogenesis in Systemic Lupus Erythematosus
15 Animal Models of Systemic Lupus Erythematosus (SLE)
SECTION 3 Mechanisms of Tissue Injury
16 Abnormalities in Clearance of Immune Complexes and Dying Cells in Lupus
17 Complement and Systemic Lupus Erythematosus
18 Apoptosis and Inflammatory Forms of Cell Death
19 Tissue Damage in Lupus: Free Radicals and Fibrosis
20 Lupus Nephritis
21 Pathogenesis of Accelerated Atherosclerosis and Vascular Injury in Systemic Lupus Erythematosus
22 Pathogenesis of Cutaneous Lupus
23 Pathogenesis of Neuropsychiatric Lupus
24 Pathogenesis of Sjögren Syndrome
SECTION 4 Autoantibodies
25 Antinuclear Antibodies, Antibodies to DNA, Histones, and Nucleosomes
26 Antibodies Against Extractable Nuclear Antigens (RNP, Sm, SS-A/Ro, and SS-B/La)
27 Other Autoantibodies: Antibodies to C1q, Lipoprotein, and Endothelial Cells
28 Pathogenesis of Antiphospholipid Antibody Syndrome
29 Drug-Induced Lupus
SECTION 5 Clinical Aspects of Lupus Erythematosus
30 Overview and Clinical Presentation
31 Skin Disease in Cutaneous Lupus Erythematosus
32 The Musculoskeletal System and Bone Metabolism
33 Lupus and the Cardiovascular System
34 Pulmonary Manifestations of Systemic Lupus Erythematosus
35 Lupus and the Nervous System: Clinical Presentation, Diagnosis, and Treatment
36 Gastrointestinal and Hepatic Manifestations
37 The Gut Microbiome and Lupus Pathogenesis
38 Hematologic and Lymphoid Abnormalities in SLE
39 Neonatal Lupus: Pathogenesis and Clinical Approaches
40 Pregnancy and Reproductive Health Issues in Systemic Lupus Erythematosus
41 Systemic Lupus Erythematosus in Childhood and Adolescence
42 Clinical Aspects of Antiphospholipid Syndrome
43 Lupus and Infections
44 Ocular, Aural, and Oral Manifestations of Lupus
45 Clinical Aspects of Sjögren’s Disease
46 Clinical Presentations of Lupus in the Kidney and Urogenital System
47 The Endocrine System and Hormones in Lupus
SECTION 6 Assessment of Lupus
48 Clinical Application of Serologic Tests, Serum Protein Abnormalities, and Other Laboratory Tests in Systemic Lupus Erythematosus
49 Differential Diagnosis and Disease Associations
50 Incomplete Lupus, Undifferentiated Connective Tissue Disease, and Mixed Connective Tissue Disease
51 Clinical Markers, Metrics, Indices, and Clinical Trials
SECTION 7 Management of Lupus
52 Principles of Therapy, Local Measures, and NSAIDs
53 Antimalarial Medications
54 Systemic Glucocorticoid Therapy for SLE
55 Immunosuppressive Drug Therapy
56 Complementary and Integrative Health Approaches
57 Specialized and Niche Therapies
58 Adjunctive and Preventive Measures
59 Management of Cutaneous Lupus Erythematosus
60 Targeted Therapies in SLE
61 Management of Lupus Nephritis
62 Management of Sjögren Disease Syndrome
SECTION 8 Outcomes
63 Socioeconomics, Disparities, and Disability
64 Prognosis and Mortality of Systemic Lupus Erythematosus
65 Future Directions: Therapeutics
66 Expanding the Opportunities to Effectively Treat Patients: Clinical Considerations
1 History of Lupus
2 Definition and Classification of Lupus and Lupus-Related Disorders
3 The Epidemiology of Lupus
SECTION 2 Pathogenesis
4 Overview of Lupus Pathogenesis
5 Genetics of SLE
6 Single Gene Defects and Autoinflammation: Relation to Lupus
7 Epigenetics of Lupus
8 The Role of the Environment and Microbiome in Lupus
9 The Innate Immune System in SLE
10 B Cells and Generation of Antibodies
11 T cells
12 Immunoregulatory Cells and Networks in Lupus
13 Cytokines in Lupus
14 Metabolic Control of Immunopathogenesis in Systemic Lupus Erythematosus
15 Animal Models of Systemic Lupus Erythematosus (SLE)
SECTION 3 Mechanisms of Tissue Injury
16 Abnormalities in Clearance of Immune Complexes and Dying Cells in Lupus
17 Complement and Systemic Lupus Erythematosus
18 Apoptosis and Inflammatory Forms of Cell Death
19 Tissue Damage in Lupus: Free Radicals and Fibrosis
20 Lupus Nephritis
21 Pathogenesis of Accelerated Atherosclerosis and Vascular Injury in Systemic Lupus Erythematosus
22 Pathogenesis of Cutaneous Lupus
23 Pathogenesis of Neuropsychiatric Lupus
24 Pathogenesis of Sjögren Syndrome
SECTION 4 Autoantibodies
25 Antinuclear Antibodies, Antibodies to DNA, Histones, and Nucleosomes
26 Antibodies Against Extractable Nuclear Antigens (RNP, Sm, SS-A/Ro, and SS-B/La)
27 Other Autoantibodies: Antibodies to C1q, Lipoprotein, and Endothelial Cells
28 Pathogenesis of Antiphospholipid Antibody Syndrome
29 Drug-Induced Lupus
SECTION 5 Clinical Aspects of Lupus Erythematosus
30 Overview and Clinical Presentation
31 Skin Disease in Cutaneous Lupus Erythematosus
32 The Musculoskeletal System and Bone Metabolism
33 Lupus and the Cardiovascular System
34 Pulmonary Manifestations of Systemic Lupus Erythematosus
35 Lupus and the Nervous System: Clinical Presentation, Diagnosis, and Treatment
36 Gastrointestinal and Hepatic Manifestations
37 The Gut Microbiome and Lupus Pathogenesis
38 Hematologic and Lymphoid Abnormalities in SLE
39 Neonatal Lupus: Pathogenesis and Clinical Approaches
40 Pregnancy and Reproductive Health Issues in Systemic Lupus Erythematosus
41 Systemic Lupus Erythematosus in Childhood and Adolescence
42 Clinical Aspects of Antiphospholipid Syndrome
43 Lupus and Infections
44 Ocular, Aural, and Oral Manifestations of Lupus
45 Clinical Aspects of Sjögren’s Disease
46 Clinical Presentations of Lupus in the Kidney and Urogenital System
47 The Endocrine System and Hormones in Lupus
SECTION 6 Assessment of Lupus
48 Clinical Application of Serologic Tests, Serum Protein Abnormalities, and Other Laboratory Tests in Systemic Lupus Erythematosus
49 Differential Diagnosis and Disease Associations
50 Incomplete Lupus, Undifferentiated Connective Tissue Disease, and Mixed Connective Tissue Disease
51 Clinical Markers, Metrics, Indices, and Clinical Trials
SECTION 7 Management of Lupus
52 Principles of Therapy, Local Measures, and NSAIDs
53 Antimalarial Medications
54 Systemic Glucocorticoid Therapy for SLE
55 Immunosuppressive Drug Therapy
56 Complementary and Integrative Health Approaches
57 Specialized and Niche Therapies
58 Adjunctive and Preventive Measures
59 Management of Cutaneous Lupus Erythematosus
60 Targeted Therapies in SLE
61 Management of Lupus Nephritis
62 Management of Sjögren Disease Syndrome
SECTION 8 Outcomes
63 Socioeconomics, Disparities, and Disability
64 Prognosis and Mortality of Systemic Lupus Erythematosus
65 Future Directions: Therapeutics
66 Expanding the Opportunities to Effectively Treat Patients: Clinical Considerations
Reseñas
Reseñas
"This book is a comprehensive and up-to-date review of Lupus Erythematosus and related syndromes written by over 100 experts in the field. The previous edition was published in 2018." ©Doody’s Review Service, 2024, Massoud Mahmoudi, DO, PhD (University of California San Francisco)
Detalles del producto
Detalles del producto
- Edición: 10
- Última edición
- Publicado: 4 de diciembre de 2023
- Idioma: Inglés
Sobre los editores
Sobre los editores
DW
Daniel J. Wallace
Daniel J Wallace MD, FACP, MACR is a board-certified internist and rheumatologist. A Clinical Professor of Medicine at the David Geffen School of Medicine at UCLA, he is the Associate Director of the Rheumatology Fellowship Program at Cedars-Sinai Medical Center, where he also serves on the Board of Governors. Dr. Wallace has authored nearly 450 peer reviewed manuscripts, 30 book chapters, eight textbooks (on lupus, osteoarthritis, Sjogren’s syndrome and fibromyalgia) and his practice includes caring for 2,000 lupus patients, the largest lupus cohort in the United States. Dr Wallace is co-chair of the Lupus Industry Council of the Lupus Research Alliance, past chair of the Lupus Foundation of America, and has served on the Board of Directors of the United Scleroderma Foundation and the Medical Advisory Board of the Sjogren’s Syndrome Foundation. He has been Chief of Rheumatology at the City of Hope and Cedars-Sinai Medical Center, and chairman of the Research and Education Foundation of the American College of Rheumatology.
Afiliaciones y experiencia
Medical Director, Wallace Rheumatic Study Center; Attending Physician, Cedars-Sinai Medical Center; Clinical Professor of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CaliforniaBH
Bevra Hahn
Dr. Hahn received her MD from the Johns Hopkins University School of Medicine, where she later trained in Rheumatology. She trained in internal medicine at Washington University in St. Louis. Dr. Hahn heads research groups that do basic studies in the immune abnormalities that cause systemic lupus erythematosus (SLE) and is developing interventions that help restore the immune response to normal. She also heads a group that studies clinical problems in patients with SLE, including accelerated atherosclerosis and potential new therapies (clinical trials). In addition, Dr. Hahn provides clinical consultations for patients with rheumatic diseases, particularly SLE. She also teaches Rheumatology and heads the administration of the Division of Rheumatology, which has 25 full-time faculty, 8 fellows and several undergraduate students, medical students, PhD students, postdoctoral trainees, and an administrative staff.
Afiliaciones y experiencia
Professor of Medicine, Chief, Division of Rheumatology, David Geffen School of Medicine at UCLA, Los Angeles, CaliforniaVer libro en ScienceDirect
Ver libro en ScienceDirect
Lee Dubois' Lupus Erythematosus and Related Syndromes en ScienceDirect